| # | Drug | Count |
|---|---|---|
| 0 | CABOTEGRAVIR AND RILPIVIRINE | 22 |
| 1 | CABOTEGRAVIR | 17 |
| 2 | RILPIVIRINE | 17 |
| 3 | DORAVIRINE | 10 |
| 4 | MARIBAVIR | 10 |
| 5 | DARUNAVIR | 9 |
| 6 | EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE | 9 |
| 7 | GLECAPREVIR AND PIBRENTASVIR | 8 |
| 8 | PREDNISONE | 8 |
| 9 | RITONAVIR | 7 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | DORAVIRINE | 10 | 0.0127 |
| 1 | DORAVIRINE, LAMIVUDINE, AND TENOFOVIR DISOPROXIL FUMARATE | 2 | 0.0064 |
| 2 | FOSTEMSAVIR TROMETHAMINE | 1 | 0.0041 |
| 3 | MARIBAVIR | 10 | 0.0041 |
| 4 | CABOTEGRAVIR SODIUM | 6 | 0.0037 |
| 5 | CABOTEGRAVIR AND RILPIVIRINE | 22 | 0.0034 |
| 6 | MARAVIROC | 6 | 0.0026 |
| 7 | RILPIVIRINE | 17 | 0.0024 |
| 8 | DOLUTEGRAVIR SODIUM AND RILPIVIRINE HYDROCHLORIDE | 4 | 0.0023 |
| 9 | CABOTEGRAVIR | 17 | 0.0021 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Cytomegalovirus pUL97 Kinase Inhibitor [EPC] | 10 | 0.0041 |
| 1 | CCR5 Co-receptor Antagonist [EPC] | 6 | 0.0026 |
| 2 | Human Immunodeficiency Virus 1 Non-Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 16 | 0.0007 |
| 3 | Cytomegalovirus DNA Terminase Complex Inhibitor [EPC] | 2 | 0.0006 |
| 4 | Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 67 | 0.0006 |
| 5 | Hepatitis C Virus NS3/4A Protease Inhibitor [EPC] | 8 | 0.0005 |
| 6 | Hepatitis C Virus NS5A Inhibitor [EPC] | 15 | 0.0003 |
| 7 | Protease Inhibitor [EPC] | 12 | 0.0003 |
| 8 | Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] | 13 | 0.0003 |
| 9 | Cytochrome P450 3A Inhibitor [EPC] | 12 | 0.0002 |